Fenofibrate

Fenofibrate belongs to the fibrate family. It works by activating a receptor located in the cell nucleus, PPAR-alpha (peroxisome proliferator-activated receptor alpha), which is especially abundant in the liver. Once activated, this receptor increases the activity of lipoprotein lipase, the enzyme that breaks down the triglycerides circulating in the blood, and it reduces the hepatic production of apolipoprotein C, a protein that normally slows this breakdown. At the same time, it stimulates HDL synthesis and enhances fatty acid oxidation through acyl-CoA synthetase.

By lowering VLDL, the lipoproteins that carry triglycerides out of the liver, fenofibrate reduces plasma triglycerides by roughly 30 to 60 percent. Its action is not limited to triglycerides: it also lowers LDL and total cholesterol while raising HDL. This profile sets it apart from statins, which mainly target cholesterol production, whereas the fibrate works above all on the triglyceride side and on the lipoproteins that carry them.

Fenofibrate is approved by the FDA in three situations: hypertriglyceridemia, meaning an excess of triglycerides in the blood, primary hypercholesterolemia, and mixed dyslipidemia, where cholesterol and triglycerides are elevated at the same time. It therefore addresses lipid abnormalities that statins alone do not always correct, particularly when triglycerides stay high. Its combined effect, lowering LDL, total cholesterol and triglycerides while raising HDL, makes it a tool for correcting the lipid profile.

The prescription aims to bring these circulating fats back toward values that protect the arteries and, in very high forms of triglycerides, to reduce a risk of pancreatitis that these marked excesses are known to promote. The physician chooses fenofibrate based on the lipid panel and the rest of the treatment. It is a decision meant for the long term: the effect is measured on blood tests, not on sensations, which explains why the treatment continues even when nothing is felt from day to day.

Fenofibrate is taken orally, once a day. For the 145 mg tablet, exposure to fenofibric acid, the active form, does not differ significantly whether taken while fasting or during a meal: it can therefore be taken with or without food, according to whatever helps you not forget it. Regularity matters more than the exact timing, because the effect depends on a stable concentration in the blood.

The half-life of fenofibric acid is 20 to 23 hours, and steady state, the point at which the concentration stabilizes, is reached after five days of regular intake. The molecule binds 99 percent to plasma proteins and is eliminated mainly through the urine, at around 60 percent. An occasional missed dose does not undo the balance, but stopping on your own makes the lipids rise again with no warning sign: any change should be discussed with the physician who monitors the panel.

The liver is the first organ to monitor. In placebo-controlled trials, abnormal liver tests occurred in 8 percent of patients on fenofibrate, versus 1 percent on placebo. In detail, ALT rose in 3 percent of patients versus 2 percent on placebo, and AST in 3 percent versus 1 percent. Creatine phosphokinase (CPK), a marker of muscle, increased in 3 percent versus 1 percent on placebo, and rhinitis was reported in 2 percent versus 1 percent. These differences, measured on lab tests, guide the pace of follow-up.

Other effects are worth knowing. Serum creatinine, a reflection of kidney function, may rise on fenofibrate, then return to its starting value after the treatment is stopped. Mild to moderate decreases in hemoglobin, hematocrit and white blood cell count have been observed after initiation. Finally, fenofibrate increases cholesterol excretion in the bile, which can promote the formation of gallstones, and cases of pancreatitis have been reported: any intense abdominal pain should prompt a consultation.

Several combinations call for caution. Combined with a statin, fenofibrate increases the risk of myopathy and rhabdomyolysis, a serious muscle injury. It can potentiate coumarin-type anticoagulants such as warfarin, with a lengthening of the INR, which makes it necessary to monitor this parameter. Bile acid sequestrant resins reduce its absorption: it should be taken at least one hour before, or four to six hours after the resin. With cyclosporine or other immunosuppressants, the risk of kidney toxicity leads to using the lowest effective dose and monitoring kidney function.

Laboratory monitoring frames this treatment. It includes liver function (ALT, AST, total bilirubin) at the start and then periodically, kidney function, CPK, the blood count and a regular lipid panel. Fenofibrate is contraindicated in severe kidney failure, defined by a creatinine clearance below 30 mL/min, in active liver disease and in preexisting gallbladder disease; moderate kidney failure requires adjusting the dose. This framework explains why the treatment comes with regular blood draws.

Fenofibrate shifts a precise blood marker: homocysteine. On treatment, this amino acid rises, with an increase of about 44 percent observed in a study published in the Lancet. This rise is specific to fenofibrate, whereas gemfibrozil does not cause it, and a direct comparison with atorvastatin and simvastatin showed that, among these molecules, only fenofibrate raises homocysteine significantly.

The body has a pathway to recycle homocysteine: it converts it back into methionine, a reaction that relies on folate, vitamin B9, with the help of vitamin B12. When folate is lacking, homocysteine accumulates. It is found in green leafy vegetables such as spinach and broccoli, in legumes and in citrus fruits such as the orange. This folate remains fragile: sensitive to heat, it loses a large part of its content with prolonged cooking. Folate supports this recycling pathway; when the plate struggles to cover the need for it, a targeted intake makes sense, in addition to your treatment, never in its place.